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ABSTRACT 
 
  
 This Interactive Qualifying Project (IQP) examined transgenic animals and their effects 
on society.  The project first describes the technology used to create such animals, then 
categorizes the types of transgenic animals created to date.   Later chapters focus on their benefit 
to society versus the ethical concerns of their creation, and documents current legislations 
regulating their use.  Finally, the project authors provide a conclusion about which transgenic 
experiments should continue or cease.  This IQP strives to relate the social needs for transgenic 
animals to the concerns raised by the development of this controversial technology. 
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PROJECT OBJECTIVE 
 
The purpose of this project on transgenic animals is to discuss the methods, means, and 
morals of this controversial new technology, to examine the effects of this technology on society. 
The methods for creating genetically modified organisms are explained in detail.  Then the 
applications and directions of the science are reviewed.  Moral and ethical issues are discussed 
regarding the benefits to society versus the cost to the animal.  Next, the laws regulating the 
development and growth of the transgenic industry are investigated.  The project aims to inform 
the reader of key relevant information regarding the debate on transgenic animals so that they 
may be able to come to a conclusion on their own about how this technology should be 
regulated. 
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Chapter-1:  Transgenic Technology 
 
A transgenic organism is genetically modified to have foreign genetic material for the 
purpose of giving it a new trait.  The technology to create one has come about fairly recently in 
man‟s history. The first transgenic organism was created in the 1970‟s; using recombinant DNA 
techniques, scientists were able to take deoxyribonucleic acid (DNA) (the genetic material that 
makes up all living things and some viruses) from one type of bacteria and insert it into another 
completely different bacteria, using a plasmid as cloning vehicle.  Although the end results lie 
inside an organism, most of the experimentation actually occurs in vitro, which in Latin 
translates to “in glass.” 
 Currently, there are many different methods for making transgenic organisms. 
Chemically competent cells can be made that take up foreign DNA, DNA can be physically 
microinjected into a cell, or a virus can be used to deliver the DNA inside a cell.  Although there 
are many different ways to create a transgenic organism, the basic ideas behind the techniques 
are the same; the DNA containing a gene, the basic unit of heredity in a living organism, must 
make it inside a cell where it can be expressed as a RNA and protein that dictate a specific 
function within the cell.  And once these organisms get made, they must be screened to 
determine whether they are transgenic.  Some screening methods test for the proteins made from 
the gene of interest, while others test to see if the DNA integrated into the host DNA, and still 
others can test the rate of expression of the gene. In the span of about four decades, recombinant 
technology has come extremely far.  The purpose of this chapter is to describe the technology for 
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making and screening transgenic animals, as a prelude to subsequent discussions of the 
technology on society. 
 
A Brief Transgenic History 
 In 1866, Gregor Mendel, a man know today as the “father of Genetics” published a paper 
called “Experiments on Plant Hybridization”, where he studied inheritance and traits in peas. He 
concluded that there were two laws governing the inheritance of plants: the law of segregation, 
and the law of independent assortment (Mendel, 1866).   In 1869, Fredrick Meischer discovered 
and isolated DNA from a cell nuclei, although it was unknown at the time that DNA was genetic 
material.  Later, in 1928, Fredrick Griffith studied transformations between virulent (disease 
causing) and non-virulent bacteria in mice. Griffith discovered what he called the transformation 
principle, noticing that by injecting mice with a live non-virulent stain of bacteria mixed with a 
dead virulent strain, the mouse would die because something from the virulent strain was being 
absorbed by the non-virulent one to transform its characteristics into a virulent strain.   In 1944, 
Oswald Avery, Colin MacLeod, and Maclyn McCarty, using the work Fredrick Griffith had 
started, made a major break through by concluding the Griffith transforming substance was 
DNA, the inheritance molecule (discussed in Avery et al, 1979).  
 Then, in 1970, Hamilton Smith discovered restriction endonucleases (enzymes that cut 
DNA at specific sequences), giving us the tools to begin to work with DNA.  Paul Berg, in 1972, 
was the first to join two strands of DNA from different sources into a single plasmid.  Finally, in 
1973, Stanley Cohen and Herbert Boyer made the world‟s first transgenic organism. Using 
recombinant DNA techniques, Cohen and Boyer altered the genome of  E. coli by adding a gene 
from another type of bacteria (Cohen et al., 1973).  In 1974, Rudolf Jaenisch created the world‟s 
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first transgenic animal by inserting foreign DNA (from an SV40 virus) into early stage mouse 
embryos; not only did the mice carry the modified gene but the mice also transferred the gene to 
their progeny (Jaenisch and Mintz, 1974). 
 Since those landmark transgenic experiments were performed, transgenic technology has 
emerged into the forefront of research, and along with it has appeared legislation for regulating 
it.  In 1975, the Asilomar conference, lead by Paul Berg, was held in Pacific Grove, California to 
discuss the potential biohazards and regulations for recombinant DNA technology.  The 
conference came to an agreement that strict guidelines should be set by the National Institutes of 
Health in the United States, and by comparable organizations in other countries, for regulating its 
use (Transgenic History, 2005).  These laws will be discussed later in Chapter-4. 
 
Recombinant DNA 
 DNA is made up of four different compounds called bases, adenine, thymine, cytosine, and 
guanine. They come together to form a double stranded chain (Figure-1). Adenine is normally 
paired with thymine, and cytosine is normally paired with guanine. The order of the bases (the 
base pair sequence) is what determines the biochemical function of the DNA molecule. Each 
organism has a specific DNA sequence that makes up their genome, and the differences in their 
genome allows each organism to express different characteristics. 
 
  
Figure 1: Diagram of the Structure of DNA.  Diagram shows 
the pairing of bases (colored rungs on the ladder) and the 
overall helical structure of DNA. 
http://commons.wikimedia.org/wiki/File:DNA_simple2.svg  
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 Recombinant DNA (rDNA) is an unnatural arrangement of DNA, made by combining 
different DNA stands (sequences) to form a new sequence that would not normally occur in 
nature.  rDNA is often called “chimeric” DNA in reference to the mythological chimera, an 
amalgamation of several animals. The DNA is usually cut using various restcriction enzymes, 
mixed, annealed to allow compatible sticky ends to adhere, then sealed using DNA ligase.   
 rDNA is usually inserted into a “cloning vehicle” or “vector” whose purpose is to help 
amplify the material.  Four different kinds of vector can be used: plasmid, virus, cosmid, or an 
artificial chromosome. Plasmids are used most frequently due to their ease of use and large copy 
number (Figure-2).  Plasmids are small pieces of circular DNA that replicate in bacteria and are 
separate from the bacterial chromosome.   The process of inserting foreign DNA into bacteria is 
termed transformation, since once inside the cell the plasmid DNA becomes expressed to give 
the bacteria new properties. 
 
 
Figure 2: Diagram of Plasmid DNA.  Figure illustrates an 
incorporated plasmid (blue circles) in a bacterial cell 
containing bacterial chromosomal DNA as its genome (red 
material). Plasmids are commonly used as DNA cloning 
vehicles.  http://en.wikipedia.org/wiki/Plasmid  
  
 
 Plasmids usually contain an origin of replication, a specific DNA sequence where DNA 
replication is initiated.  Also contained within the vector is a multiple cloning site (MCS) that 
contains many restriction sites to allow flexibility in inserting various types of cut DNA.  Lastly, 
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plasmids contain a selectable marker that allows cells containing it to be selected for. 
 
Methods for Inserting rDNA Into Cells 
 There are various ways for inserting foreign DNA into a cell, including microinjection, 
chemicals, electroporation, viruses, or sperm manipulation.  When a plasmid, virus, or 
bacteriophage is used to transfer genetic materials it is called transduction.   In higher-level 
organisms like eukaryotes (plants and animals), the genetic incorporation of  DNA is called 
transfection.  
 
DNA Microinjection 
 Microinjection is the most reliable method for introducing DNA into a cell.  This 
technique was commonly used to create most of the early transgenic animals (Gordon et al., 
1980) (although this technique was not used to create the very first transgenic animal which used 
virus delivery; Jaenisch and Mintz, 1974).  Using a newly fertilized egg created by in vitro 
fertilization, an egg is held in place by a microtube suction device, and a separate glass needle 
approximately 0.1 µm in diameter is used to insert transgenic DNA into the male pronucleus 
(will be discussed in more detail below).  
  
DNA Chemical Methods 
 Some bacteria have the ability to uptake extra-cellular DNA, but this process is rare in 
nature.  However, some bacteria can be made “competent” to take up DNA by using various 
salts, especially calcium or rubidium.  Chemical competency is a good method for transforming 
bacterial cells.  For eukaryotic cells, chemical methods include complexing the DNA with a 
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positively charged polymer, then binding that polymer to the cell membrane.  The DNA complex 
is released into the cell, where is can be taken it to the nucleus and expressed. Human and mouse 
cells can be efficiently and easily transformed when exposed to the packaged DNA (Segura and 
Shea, 2002). 
 
DNA Electroporation 
 DNA is a negatively charged molecule due to the presence of phosphate groups in its 
backbone.  So when it is exposed to a current of electricity, DNA will migrate towards the 
positive anode.  Electroporation is performed by exposing a cell culture mixed with transgenic 
DNA to a pulse of high voltage electricity.  The DNA is pulled through the cell membranes by 
the electric current. Once inside the cell the DNA moves through the cytoplasm and becomes 
incorporated with the genetic material inside the cell (Taconic, 2003). 
 
DNA Viral Delivery 
 One of the most sophisticated methods for introducing foreign DNA into cells uses viruses.  
DNA viral delivery was used to create the world‟s first transgenic animal (Jaenisch and Mintz, 
1974).  Jaenisch‟s group infected mouse embryos with a virus containing SV40 sequences, 
creating the first transgenic animal. Normally a virus would destroy the host organism but using 
genetic engineering it was altered and allowed the viral DNA to incorporat into the genome. This 
method involves encasing the altered viral DNA in a protein coat that will allow the virus to 
infect the target cells. Viral delivery is efficient, and improves the chances of transgene 
expression.  In some case, like the Adeno-associated viruses (AAV), the viral DNA inserts at 
specific host DNA locations. The two biggest limitations of viral delivery are the size of the 
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DNA molecule that can fit inside the virus, and the chance that a chimera will be made without 
the ability to pass on its transgene.  
 
Sperm Manipulation 
 Some scientists are trying to develop new ways to incorporate modified DNA into a cell by 
using recombinant sperm.  In 2004, Noriyoshi Sakai and Kayoko Kurita were able to create a 
transgenic fish by modifying sperm from a zebrafish to perform in vitro fertilization.  The 
transgenic fish grew into a fully developed adult (Kurtia et al, 2004). This technique is being 
expanded to other animals. 
 
Transgenesis by Manipulation of a Pronucleus 
 Now that we have described ways for making rDNA for for inserting it inside cells, we 
turn our attention to the two main ways for making a transgenic animal: 1) manipulation of the 
pronucleus of a newly fertilized egg, and 2) manipulation of embryonic stem cells.  Traditionally 
the most common method used to create a transgenic animal was to manipulate the male 
pronucleus in a newly fertilized egg.  The technique begins by harvesting eggs from a super-
ovulating female made by injecting her with specific hormones. The eggs are fertilized in vitro, 
but before the male and female pronucleus fuse to become a nucleus, the male pronucleus 
because of its larger size is microinjected with the DNA containing the gene of interest (Figure-
3).  The fertilized eggs are then cultured to the blastocyst stage (about 5 days), where the embryo 
looks like a hollow ball of cells. Finally, the blastocyst is implanted into a pseudopregnant 
mother where it will develop into a transgenic animal. 
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Figure-3:  Microinjection of Foreign DNA into the 
Male Pronucleus.  A large pipette (left side) is used to 
hold a fertilized egg in place with gentle suction.  The 
micropipette for injecting DNA (right side) will target 
the DNA to the male pronucleus (center left) (Oregon 
Health, 2009).  
 
 
 
The male pronuclear microinjection method is very useful with a wide variety of species, 
and it has been proven reliable. Although DNA microinjection into a male pronucleus works, 
there is no control over where the transgene will insert itself into the host genome. It could insert 
into a control gene necessary for cell function and result in a low survival rate for the 
transformed cells.  If the transgene incorporates into an active region of the host chromosome, 
the surviving cells will express the transgene.  Male pronuclear DNA microinjections create a 
pure transgenic animal in which all cells contain the transgene, while other techniques like 
embryonic stem cell microinjection create chimeras. 
 
Transgenesis by Manipulation of ES Cells 
 The second main method for making a transgenic animal is to manipulate embryonic stem 
(ES) cells.  An embryo is prepared by in vitro fertilization, then grown about 5 days to the 
blastocyst stage.  ES cells are found in the inner cell mass of the blastocyst (Figure-4), and they 
are isolated using a microneedle.  The harvested ES cells are cultured in vitro in a medium 
containing leukemia inhibitory factor, which prevents them from differentiating.  These cells are 
then manipulated to take up foreign DNA using any of a variety of techniques.  One of the 
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biggest benefits of this process is the ability to screen growing ES cells to verify they are actually 
expressing the recombinant DNA.  For example, if the injected plasmid DNA contains the gene 
for neomycin resistance, the ES cells can be grown in neomycin and only those that grow will 
contain the plasmid (and its transgene).  The recombinant screened cells are then microinjected 
back into a blastocyst which is implanted into a recipient uterus (Stem Cell Basics, 2006).  Note 
that only the injected ES cells contain the transgene, not the other ES or surrounding trophoblast 
cells of the blastocyst, thus the founder animals produced using this ES technique are chimeras, 
containing some cells that are transgenic and some not.  But usually each organ has some 
transgenic cells (Wheeler et al, 1991), including their reproductive organs, so by selectively 
breeding chimeras a pure transgenic line can eventuallly be created (Taconic, 2003).  
 
 
 
Figure-4: Diagram of a Cross Section of a Blastocyst.  
Shown are embryonic stem cells (green) which are used to 
create transgenic animals.  
http://en.wikipedia.org/wiki/Inner_cell_mass 
 
 
 
 
 
 
  
DNA Homologous Recombination 
 Both male pronuclear and embryonic stem cell techniques are effective at producing a 
transgenic animal, but DNA microinjection generally allows no control over where a transgene 
inserts into the host genetic material.  This problem can be overcome using the natural process of 
homologous recombination (Figure-5).  In a eukaryotic cell, DNA is organized into 
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chromosomes that allow the genetic material to be condensed and regulated.  In higher 
organisms like plants and animals that reproduce sexually, chromosomes are diploid (meaning 
they have two sets of chromosomes), one from their mother and one from their father.  During 
the sex cell replication process of meiosis, matching chromosomes pair (diagram left), and can 
exchange small equivalent pieces of their DNA (diagram center) in a process called a crossover, 
to create new chromosomes (diagram right), allowing an increase in genetic diversity from 
parent to offspring.   
 
 
Figure 5: Diagram of Homologous 
Recombination.  During meiosis, homologous 
chromosomes pair (diagram left), which 
sometimes allows crossovers to occur (diagram 
center) to create a new chromosome (diagram 
right).  This process can be used to target DNA to 
a specific chromosomal location in transgenesis.  
http://www.web-
books.com/MoBio/Free/Ch8D1.htm  
  
 
 
 During transgenesis, the use of this natural process of homologous recombination 
accurately targets the new foreign DNA to a specific host chromosome location (Bronson and 
Smithies, 1994).  The vector DNA is modified to contain sequences identical to regions of host 
DNA constituting the desired location for insertion.  The vector is engineered so these host DNA 
sequences flank the transgene.  After microinjection of the vector, the host sequences in the 
vector exchange place with its matching region on a host chromosome, bringing along the 
transgene.   The modified ES cells are then injected back into a blastocyst as described before.  
 Although homologous recombination allows site specific integration, to use this process 
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the sequence of an organism‟s chromosome must be known in advance to allow construction of 
the plasmid.  Homologous recombination is also a good technique for performing DNA “knock 
outs” in which specific host genes are targeted and stuffed with useless DNA or removed.  A 
“knock out” is where the DNA is engineered to remove a gene, while a “knock in” adds one.   
These are valuable tools when determining the function of specific genes in the development of 
an organism, because the expression of a protein can be removed and the effects of its absence 
analyzed.  Knockouts and knock ins would not be possible without the precise gene targeting 
allowed by homologous recombination. 
 
Transgenesis by Somatic Cell Nuclear Transfer 
 Somatic cell nuclear transfer (SCNT) involves the removal of a nucleus from a somatic 
cell, most likely a skin cell, and the implantation of that nucleus into an enucleated egg by 
microinjection.  After the nucleus has been transferred, the egg is developed into a blastocyst, 
and implanted into a surrogate mother. The resulting offspring is genetically identical to the 
donor of the skin cell nucleus.  This SCNT process was used to create the worlds first cloned 
mammal, Dolly the sheep.   With respect to transgenesis, the injected nucleus can also be 
engineered to be transgenic.  The nucleus can be prescreened before the organism is developed to 
ensure its uptake of the transgene (Nuclear Transfer Technology, 2005).  This method produces 
an incredible strain on a cell because it is completely reprogrammed, but the end result will be a 
100% transgenic animal.   
 The SCNT technique has mostly been done in mice, but in 2001, SCNT was performed in 
human cells that developed into early embryos (Cibelli et al, 2001).  However due to the 
controversial nature of egg collection in humans, the lack of human embryo survival to late 
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stages, and the current legal ban on the process, few further human SCNT experiments have been 
performed.   An infamous experiment in 2005 by Hwang‟s lab in Korea claiming to have created 
human cloned cells by SCNT (Hwang et al., 2005) was subsequently withdrawn for fraud. 
 In 2006, scientists discovered how to reprogram somatic skin fibroblast cells back into ES-
like stem cells by inserting DNA encoding 2-4 key transcription factors that induce de-
differentiation (Vogel, 2006; 2008). This technology is especially useful in medicine because a 
patient's own skin cells can be used to regrow diseased tissues, with cells genetically identical to 
the patient eliminating graft rejection.  And the cells can even be engineered to produce a 
product, so for example a skin cell could be reprogrammed to produce insulin and then implanted 
into the pancreas to treat diabetes (The Future of Cloning, 1998). 
 
Methods for Transgene Detection 
 The process of making transgenic animals is not efficient.  Many resulting offspring do not 
take up the transgene, or they take it up but do not express it, so it is important to screen 
offspring for transgene integration and expression.  Many methods for the detection of a 
transgene or its by products have been developed.  Some screen for the transgene DNA itself, 
some for the mRNA produced from the transgene, and some screen for the transprotein encoded 
by the mRNA.  Some transgenic techniques even allow screening before the embryo is 
developed, but most screening occurs when the newborn founder animal is about 3 weeks of age. 
And even if a founder proves positive, it is still important to continually check for transgene 
expression through the course of the animal‟s life.  
 Southern blotting is a technique that detects a specific DNA sequence in a complex mixture 
of  DNA.   So for example, this technique can detect the presence and copy number of a 
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transgene inserted in the genome of an animal.  The DNA most commonly tested is attained from 
tail, ear, or white blood cells.  In the Southern process, the organism‟s genome is cut using 
restriction enzymes into smaller fragments (Figure-6). These fragments are then separated by 
size in a process called gel electrophoresis (diagram upper center).  Using electricity to pull the 
negatively charged DNA through a gel, it can be separated based on size.  The DNA in the gel is 
then denatured to form single stranded DNA (to allow it to anneal to a probe), and the DNA is 
transferred to a paper like membrane (diagram upper right). The DNA on the membrane is 
washed with a solution containing a probe that contains a complementary DNA sequence to the 
transgene sequence of interest (diagram lower center).  The probe has either a radioactive or 
fluorescent label attached to it to allow visualization (lower right). 
 
 
  
 
Figure 6: Diagram of the Southern 
Blot Process.  This procedure is often 
used to assay the presence and copy 
number of a specific transgene in a 
founder animal‟s genome.  
http://www.molecularstation.com/image
s/southern-blot.jpg 
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 Northern blotting is another technique used to determine the expression of a transgene.  It 
is very similar to Southern blotting, hence its name, but cellular RNA is electrophoresed instead 
of cellular DNA.   In this case, the RNA on the membrane is hybridized to a transgene probe, and 
a signal indicates the presence of transgene mRNA in the cell.  
 Another very effective method for detecting transgene mRNA is quantitative Real-Time 
Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR). This method uses the mRNA 
from a cell and an enzyme called reverse transcriptase to create complementary DNA to the 
mRNA.  DNA primers are engineered to bind a portion of the transgene sequence, then an 
enzyme called DNA polymerase binds to the primers and amplifies the target DNA sequence.  
The primer DNA is combined with a molecule called SYBR green that becomes extremely 
fluorescent when complexed with double stranded DNA.  The increase in fluorescence is a 
measure of signal amplification from the transgene mRNA. 
 Western blotting is also very similar to Southern and Northern blotting, but in this case 
cellular protein is electrophoresed.  The membrane is hybridized to an antibody against the 
transprotein, and a signal indicates the presence of the transprotein.   
 Western blotting is not the only technique that can be used to determine the presence of a 
transprotein.  Enzyme Linked Immunoabsorbent Assays (ELISAs) also screen for the production 
of a transprotein. A small plastic well is coated with antibodies specific to the protein of interest, 
then the well is filled with a test solution potentially containing the transprotein (i.e. lysed blood 
from a founder animal). The antibodies coating the well hold the transprotein in place.  Non-
bound proteins are washed away, then a second antibody against the transprotein (but conjugated 
to a fluorescent or radioactive label) is added to the well to detect the presence of the 
transprotein.   ELISAs are far more quantitative than Western blots. 
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 In some cases, the presence of the transgene confers new visible properties on the founder 
animal, and these can be used to determine the uptake and expression of a transgene. In the case 
of bacteria, a gene encoding resistance to an antibiotic can be engineered and inserted into their 
genome. These bacteria will grow on a plate containing the antibiotic, only those who have taken 
up the transgene will survive.  Or a transgene can be engineered to make a cell glow a different 
color.  Green Fluorescent Protein (GFP) is the golden child reporter for expression.  GFP can be 
fused with the transgene, so when the transgene is expressed so is GFP (Figure-7). 
 
 
 
 
Figure 7: Picture of a Transgenic 
Fly Expressing Green Fluorescent 
Protein.  Reporters like GFP can be 
used to help determine expression of a 
transgene.  http://genetik.fu-
berlin.de/institut/en_GFP_fly3.jpg 
 
 
 
 
 
 These techniques together constitute the main ways founder animals are screened for 
transgene integration and expression.  Each transgenic experiment brings us closer to more fully 
understanding genetics, and creates new animals for aiding mankind.  New techniques are 
always emerging to make the process more efficient.  Transgenic technology has the ability to 
greatly assist in man‟s struggle, and with a caring eye and guiding hand it will. 
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Chapter 2: Transgenic Applications 
 
Benjamin Seicol 
 
Introduction 
Transgenic technology, the ability to recombine DNA between species, can be applied to 
almost every species on earth, ranging from complex mammals down to unicellular organisms.  
In the past century, many transgenic animals, plants, and bacteria have been created to explore 
this rapidly developing technology.   Transgenic applications can be divided into five major 
categories based on the purpose of the transgene: scientific models, disease models, 
xenotransplanters, transpharmers, and food sources.  Throughout this chapter, several examples 
of transgenic animals will be documented to help illustrate their classification and benefit to 
society, as a prelude to discussing their ethics in the next chapter. 
 
Scientific/Biological Models 
 
Commonly referred to as scientific models, or biological models, this very broad category 
of transgenic animals sheds light on specific protein functions in vivo.  This is often done by 
either over-expressing a specific protein whose function is in question, or by knocking out its 
expression.   Information gained from this class of animals on the function of a protein is used 
when creating transgenic animals of any other category.  Understanding specific protein 
functions and mechanisms is vital for developing any successful transgenic animal to benefit 
society.  As more of the mechanisms underlying biological systems become clear, our ability to 
regulate these natural pathways increases dramatically.   
Examples of animals in this category include: a transgenic monkey engineered to express 
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jellyfish green fluorescent protein to study primate gene expression (Chan et al., 2001), a smart 
mouse that over-expresses the NR2B subunit of the glutamate receptor to learn faster and retain 
memories better than wild type mice (Tang et al., 1999), and knock out mice used to study the 
developmental effects of specific proteins.   
 
Disease Models 
 
Disease models are created to mimic specific aspects of a human disease, to aid our 
understanding of disease onset, and to serve as a method of rapidly screening potential therapies 
on a model other than humans.  In these models, human genes implanted animals to allow them 
to mimic certain aspects of a human disease. A transplanted gene must be introduced into the 
host animal to create a platform for the disease. This creates nearly identical symptoms in the 
host animal that a human would exhibit, allowing scientists to test new medications and 
treatments without risking human lives.  Like other model organisms, disease models are often 
done on mice and flies since they are so readily manipulated in lab situations.  Modeling human 
diseases with transgenic animals is among the most prominent category of transgenic animals, as 
they are required in order to proceeding to clinical trials, the final step preceding the release a 
new pharmaceutical.  Both Alzheimer's disease and Huntington's disease have each been 
modeled in mice and other animals, paving the way for greater understanding of the molecular 
mechanisms underlying these devastating diseases.   
 
Alzheimer's Mouse  
 
Alzheimer's disease (AD) is a neurodegenerative disease that primarily leads to senile 
dementia.   The pathology of this disorder is characterized by the formation of amyloid plaques, 
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neurofibrillary tangles, and brain atrophy.  Amyloid plaques are primarily made of small 
proteins, usually 40-42 amino acids in length, called the β-amyloid peptide (Gurney, 2000). 
Tangles, on the other hand, are twisted fibers formed inside dying cells, and are composed of a 
protein called tau.  These plaques and tangles show up mostly in the cerebral cortex and 
hippocampus where they disrupt the processing of information.  This localization makes sense, 
since those regions of the brain are responsible for both memory and cognitive thought.  The 
mechanism, by which neurotoxic β-amyloid is believed to be generated, involves the incorrect 
processing of amyloid precursor protein (APP) as shown in Figure-1.  This modification is 
dependent on cleavage sites located on each end of the β-amyloid peptide region of APP (shown 
as blue in the figure). 
 
 
Figure-1:  Diagram of 
the Formation of β-
Amyloid in Alzheimer’s 
Disease.  Neurotoxic β-
amyloid (blue) is formed 
by the cutting of the beta 
and gamma secretases at 
sites located on each side 
of the peptide.  Mutations 
on each side of the 
peptide, as shown below 
the sequence, can also 
accelerate production of 
the toxin.  (Gurney, 2000) 
 
 
 
 
 
Several different mutations are known to affect production of β-amyloid proteins in families 
prone to Alzheimer‟s.  The figure shows two different mutations, one at each cleavage site.  
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These mutations accelerate the cleavage of APP to produce neurotoxic β-amyloid.   
Based on these findings, scientists at WPI and the former Transgenic Sciences Inc, 
cloned the gene for an early onset APP mutation (the Indiana mutation, denoted as V717F and  
shown on the right in Figure-1) and inserted it into a mouse line (Games et al., 1995); thus 
creating the world‟s first Alzheimer‟s model.  Earlier attempts to produce such models had 
failed, but the 1995 model succeeded, as the mice developed amyloid plaques and showed 
similar degeneration of neurons to an Alzheimer‟s patient.  This model taught us that β-amyloid 
formation is necessary and sufficient for initiating the disease.  However, no neurofibrillary 
tangles formed.  In order to successfully model the disease, subsequent models inserted a tau 
mutation that is more easily hyperphosphorylated.   Now, both hallmark lesions have now been 
modeled.  These models have already been used to screen for drugs to block beta and gamma 
secretases from forming more β-amyloid.  Specifically, the 1995 model was used by Elan 
Pharmaceuticals to create a vaccine capable of removing β-amyloid from brains (Schenk et al., 
1999).  The vaccine has already moved into human clinical trials, where other disease model-
inspired treatments have joined it.  These models could lead to a greater understanding of what 
causes Alzheimer‟s and, therefore, how to prevent it.   
 
Huntington's Mouse  
Huntington‟s disease is a neurodegenerative disorder classified as a “triplet repeat 
disorder” because it is characterized by excessive repetition of 3 nucleotides – CAG (Doherty et 
al., 1999).  Normally, the Huntingtin gene (HTT) contains a segment within the coding region 
containing anywhere from 3-30 CAG trinucleotide repeats.  Patients with Huntington‟s disease 
undergo an expansion of this section, resulting in 35-121 repeats, which leads to abnormal 
26 
 
production of polyglutamine and nuclear aggregates (Gurney, 2000).  A mouse model of this 
disease can be generated by transgenesis of DNA carrying highly expanded CAG repeats.  
Transgenic mice model this disease better than the Alzheimer‟s models, as these mice replicate 
the movement disorder and weight loss experienced by people with Huntington‟s (Doherty et al., 
1999).    
Recently, a new model has been created using an animal more advanced than a mouse.   
Huntington‟s disease was successfully modeled in primates, marking one of the most major 
breakthroughs in the history transgenic technology (NIH.gov, 2008).  The research team 
developed the rhesus macaque monkey model by introducing altered forms of the HTT gene into 
macaque eggs.  For the first time ever, five monkeys were born mimicking a specific human 
disease (NIH.gov, 2008).  The potential benefits of this transgenic application in monkeys will 
help scientists to accurately target Huntington‟s in humans. 
 
Xenotransplanters 
Over the past 2 decades, the number of organ transplants conducted in the United States 
each year has increased dramatically.  As the demand for viable organs rises, the supply from 
donors cannot keep up.  In 1996, 20,000 transplant procedures were done in the US, yet 
approximately 50,000 persons were left awaiting organ donations at the end of that year (Pearson 
and Chapman, 1998).  Despite a significant increase in our capacity to perform transplantations 
due to improvements in medical technology, recipients awaiting organ donation have more than 
tripled since 1988.  A possible alternative organ source exists that could potentially eliminate this 
demand for donated human organs: using transgenesis to create large mammals called 
xenotransplanters, which can be used as human organ generators.  Xenotransplantation is defined 
as a “procedure that involves the use of live cells, tissues, or organs from a nonhuman animal for 
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transplantation” (Pearson and Chapman, 1998). 
In order to successfully transplant a donated organ, it must be histocompatible with the 
recipient.   Complete compatibility can rarely be found, so immunosuppressive drugs are usually 
given to the transplant patient to prevent an immune response.  Normally, the body rejects organs 
(or any tissues) that lack histocompatibility.  Antigens on the surface of foreign cells are 
recognized to induce the appropriate immune response.  This same system results in the rejection 
of a transplanted organ, usually resulting in the patient‟s death.  Therefore, xenotransplanters are 
engineered not to express antigens viewed as foreign in humans.   
The most promising animal for xenotransplant research is the pig, mostly due to its 
closely matching physiology to that of humans.  Also pigs are far cheaper and more established 
for large-scale production than monkeys, which are physiologically more like humans.  The 
primary problem with organs from a pig is the presence of alpha-1,3-galactosyltransferase an 
enzyme that adds the sugar galactose onto proteins on the surface of the cells (shown as circles in 
Figure-2).  This is the primary antigen that would be recognized as foreign by the human 
recipient resulting in immuno-rejection of the organ (Soin and Friend, 2000).   Thus in 2002, 
scientists created pigs in which the galactosyltransferase gene has been knocked out, so the 
organs do not have galactose on their surface (Lai et al., 2002).  These pig organs are currently 
being tested for transplants into baboon models, but the sufficient data are not yet available. 
28 
 
 
 
 
 
 
Figure-2:  Diagram of Some Key Sugars Attached to 
Proteins Following Post-Translational 
Modifications.  Shown are various sugar residues (key 
on the right side) generally found on proteins in various 
species.  In regards to xenotransplantations, the specific 
sugars may vary between mammals.  For example, 
galactose (denoted by circles) is removed to increase 
the histocompatabilty of organs from xenotransplanter 
pigs (Soin and Friend, 2000).  Primarily, these unique 
structures related to transpharming, because scientists 
desire sources that are easier to work with in lab.  
However, the protein produced must be altered to 
mimic human‟s structures.  So if many synthetic steps 
are required another, more similar, source is required 
(Houdebine, 2009). 
 
 
 
 
 
 
 
Transpharmers 
 
Proteins were first used as pharmaceuticals almost 100 years ago, with the use of insulin 
isolated from pig pancreas.  Unfortunately, proteins like insulin are too complex to synthesize 
from amino acids for mass production, and tissue donations for protein isolation get far too 
expensive in large-scale operations.  Living organisms, such as bacteria, offer a far more 
practical (and affordable) option, and have been used since 1973 with the first transgenic 
bacterium (Cohen et al., 1973).  Although bacteria demonstrated the ability to produce a variety 
of active proteins, extensive use of bacteria is not the best option since they cannot accomplish 
the post-translational modifications of higher organisms.  Without these modifications, some 
bacterially produced proteins are inactive in humans, and must undergo expensive activation in a 
lab.  Synthetic reactions can activate the protein, but additional changes also drive up costs.  
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Animals and plants contain post-translational modifications similar to our own (Houdebine, 
2009), so over the years the production processes have moved to higher organisms such as these.   
Many different biological systems are available for researchers, most of which are detailed in the 
Houdebine review and are shown above in Table 1.   
 
Table 1:  A Comparison of Six Methods for the Production of Pharmaceutical Proteins. 
 
The + signs denote relative levels of production for comparison purposes.  Note that transgenic animals (the 
column on the far right) are well suited for post-translational processes, including glycosylation to produce 
biologically active proteins while preventing rejection type reactions (Houdebine, 2009). 
 
 
The production of proteins in farm animals (and plants) is termed transpharming.  
Although animals have been produced that manufacture foreign proteins in blood, milk, and egg 
whites (Table 2), production in the animal‟s blood has mostly been replaced by production in the 
milk since the proteins in the former case directly affect the animal‟s physiology.  Milk is the 
most promising production system that transgenesis can manipulate, and is definitely the highest 
yielding system available (Houdebine, 2009).   
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Table II:  A Comparison of Transgenic 
Protein Production in Blood, Milk, and 
Egg Whites.  The + signs denote relative 
levels of production for comparison 
purposes.  Note that production in milk is 
especially well suited for high levels of 
production of highly stable proteins, that 
are easy to isolate (Houdebine, 2009). 
 
 
 
 
 
 As an example of an animal in the transpharmer category, ATryn® is the world‟s first 
FDA approved transpharmed drug, produced in the milk of transgenic goats as engineered by 
Genzyme Transgenetics Corp (GTC) of Framingham, MA (Atryn, 2009).  These goats produce 
the anticoagulant anti-thrombin at high levels in a form that is biologically active.  
Transpharming has also been applied to cattle, with the production of a line of cows producing 
lactoferrin in their milk, a key ingredient in human milk that is missing in cow‟s milk 
(Lactoferrin, 2008). 
 
Transgenic Food Sources 
The final category of transgenic technology to be discussed in this chapter is genetically 
modified food sources.  The goal of this group is to produce animals (and plants) that grow to 
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large sizes on less food intake, without increasing costs.  Transgenic food animals are not yet  
commercially available, due to the ethical and safety issues associated with their possible escape 
to interbreed with wild type animals, and problems associated with growth hormone production 
in mammals.  In one such experiment, scientists spliced the gene for Human Growth Hormone 
(HGH)  into a pig‟s genome. The pig, given the name “Superpig” (or the Beltsville pig), grew 
larger and faster than normal pigs, while consuming less food (Pursell et al., 1997).  
 Unfortunately, Superpig suffered from several painful side effects of the transgenesis, 
including   arthritis, gastric ulcers, stomach lesions, lack of coordination, and severe muscle 
weakness.  In response to this, scientists halted all further tests involving farm animal 
transgenesis with human growth hormone.  While it seemed to be a good idea, the negative side 
effects of human growth hormone on pigs make it ethically wrong to continue such growth 
hormone experiments in mammals (Rexroad, 1994). 
In fish, on the other hand, far less devastating side effects were observed when they were 
provided with growth hormone genes (Devlin et al., 1997).  These salmon grow 3-6 times faster 
than normal salmon, with less food intake, so are very well suited for aquaculture (Fletcher and 
Shears, 2002).  These salmon reach marketable size a year earlier than other commercially 
produced salmon.  Although not yet available commercially due to ethical concerns if they 
escape and interbreed with wild type salmon, Aquabounty Technologies the company marketing 
them, hopes they will be approved by the FDA within the next few years, giving hope for a new 
food source (Aquabounty, 2009). 
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Conclusion - Chapter 2 
 Many of the applications discussed have become quite well established, or at least have 
shown a lot of potential.  Transpharming to produce pharmaceutical proteins, and  xeno-
transplanters for producing organs for transplants, are becoming completely practical ideas.  
Additionally, disease and biological models using transgenic animals have already proven vital 
in the development of new pharmaceuticals.  Animal testing has become very socially accepted, 
partially due to the incredible benefits that have already been observed.  Future treatments, 
derived from this research, may alleviate many “incurable” diseases that humans face today.  The 
broadest application to transgenic technology has been in the production of food crops.  Thanks 
to our infrastructure for mass production of these plants, commonly observed low yields are less 
of a concern.  Most of the ethical questions raised by the controversial research surrounding 
transgenesis do not apply to plants, with exception of environmental concerns.  But transgenic 
plants hold the promise of feeding billions of people around the world. 
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Chapter–3: Transgenic Ethics 
Benjamin Parkhurst 
 
Humans have relied on animals for millennia for food, clothing, transportation, 
protection, and many other reasons. Animals have also been used to produce a wealth of 
knowledge in the field of science, from anatomical and medicinal practices to neurological 
applications.  Despite the vast advancements we have made in scientific knowledge, many argue 
against animal testing for reasons of cruelty, religion, morality, and the environment. As 
intelligent beings we are obligated to consider both the benefits as well as the costs of using 
living creatures as tools.  For transgenesis, the subject of this IQP, the power to manipulate the 
genome of plants and animals comes with great responsibility.  This chapter will examine the 
ethics involved in animal research in the field of transgenics.   
Any time emotion is the primary ingredient involved in a situation there will never be a 
completely right or wrong answer, there will only be opinions. Some people see any use of 
animals for human benefit as wrong, and that under no circumstances should animals be used for 
experimentation. Others will always view human needs above those of an animal, and would 
permit all uses of “lower” beings for experimentation. It is obvious that without the use of 
animal experimentation we would not have nearly as much scientific knowledge as we currently 
do.  It is important to understand both sides of the argument to make a solid ethical argument. 
 To understand the modern day animal rights arguments, a brief history of animal 
research, along with early animal experimentation opposition must be understood.  Then 
different ethical perspectives including religion will be investigated.  Some of the specific animal 
experiments described in previous chapters will be morally evaluated to give us a better 
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understanding of the ethical concerns involved with transgenics. Although the legalities involved 
with transgenic animals will be reviewed in the next section, this section will briefly discuss the 
ethics behind the laws.  For transgenics, with such great scientific power left up to the politicians 
to determine how far it will go, it must be considered who actually holds the moral standing to 
determine what types of transgenic study will be allowed.    
 
Brief History of Animals in Research 
Animals were first used in experiments in ancient times that mainly focused on 
anatomical curiosity. Most of the early research done with animals was vivisection (dissection), 
and was done without anesthesia and was occasionally conducted while the animals were still 
alive.  Some of the first experiments were conducted in the third century BC by Alexandrian 
physicians, Herophilus and Erisistratus. It has been recorded that they examined the functional 
differences between sensory nerves, motor nerves, and tendons (Singer, 1957).  From the 
beginning of animal experimentation, records indicate scientists reactions to working on animals. 
Galen of Pergamum (129-199 AD) preferred to vivisect pigs to “avoid the unpleasant expression 
of the ape” (Maehle and Trohler, 1987).   
 There is little documentation of animal vivisection from the Dark Ages.  In a time when 
animals were experimented on, as well as human criminals, often in public lectures on anatomy, 
few concerned themselves with the morality of these actions. The Christian Church at this time 
viewed only humans as possessing a soul and the power to reason.  Animals existed only for 
human needs and were bereft of moral status (Linzey, 1989).  
 It was not until the 16
th
 century that rise of modern biomedical studies began.  At this 
time, many things previously not understood about the body such as circulation, digestion, and 
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respiration were seen to have physiological explanations. With this in mind the use of animals 
for experimentation began to increase and continued into the 20
th
 century. Another landmark of 
physiology came from Claude Bernard (1813-1878), when he declared that a precise approach to 
experimentation must involve the study of one parameter while holding extraneous variables 
constant (this remains a fundamental approach in modern science). In one paper he presented his 
opinion on the experimental use of animals; “It would be strange indeed if we recognized man’s 
right to make use of animals in every walk of life, for domestic service, for food, and then 
forbade him to make use of them for his own instruction in one of the sciences most useful to 
humanity” (Bernard [1856], 1957).  Around 1850, the anesthetic properties of ether were 
discovered which would allow the operation of animals to be conducted without putting them 
into any pain. This made surgical procedures involving animals a norm in many facilities across 
Europe. Records show that the number of animal procedures involving research animals 
increased from 311 in 1880 to over 95,000 in 1910 (Monamy, 2000).  The discovery of the 
bacterium responsible for tuberculosis in 1882, and the diphtheria antitoxin in 1894 (which 
rapidly reduced infant mortality from 40% to 10% in those afflicted), whose breakthroughs were 
accomplished through animal research, led to a broader public acceptance of animal 
experimentation (Turner, 1980).  
In the twentieth century, the continued use of animal experimentation along with the 
relatively low restrictions on animal use, lead to numerous medical breakthroughs.  In 1989, the 
American Medical Association on Scientific Affairs published an impressive list of medical 
advances made possible through research using animals. This list includes expanding our 
knowledge of autoimmune diseases, acquired immunodeficiency syndrome (AIDS), anesthesia, 
behavior, cardiovascular disease, cholera, diabetes, gastrointestinal surgery, genetics, 
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hemophilia, hepatitis, infant health, infection, malaria, muscular dystrophy, nutrition, 
ophthalmology, organ transplantation, Parkinson‟s disease, rabies, radiobiology, reproductive 
biology, shock, the skeletal system, toxoplasmosis, yellow fever, and virology.   
Thus, animals have been used for generations in various scientific experiments, from the 
most basic dissection to the current science of transgenic genetic alteration.  And there has been 
an element of human emotion involved that has made it unclear exactly when the ends justify the 
means, so the next section will examine both the positives and negatives of transgenic research. 
 
Cost Versus Benefit of Transgenic Animals 
The relatively recent discovery of transgenic technology is a great tool that has already 
been used to make significant advancements in medical and food resources, as discussed in 
Chapter-2.  Just as the medical advancements of previous centuries came at a price, so do 
transgenic experiments.  To make a valid ethical judgment on transgenic animals, there must be 
an understanding of what is gained and lost from the research.  
 
The Cost of Transgenesis 
People against animal experimentation argue for animal welfare, religion, and morality, 
and the environment. Animal rights groups such as the ASPCA (The American Society for the 
Prevention of Cruelty to Animals) and PETA (People for the Ethical Treatment of Animals) have 
lobbied for years for limited and regulated animal experimentation.  From the outset it must be 
noted that some types of transgenic research do cause some animal pain or even death.  The 
super pig, whose genome incorporated HGH (human growth hormone), experienced a very 
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painful period of time before it was euthanized. Disease modeling, in which an animal is given a 
certain human disease, or aspects of a disease, can create similar ethical issues. 
Many different arguments are made about the use of animals in today‟s society. Societal 
and religious beliefs cause much debate about exactly how animals should be used.  Some people 
believe that the use of mice creates less of an ethical dilemma because they are not sentient 
creatures such as monkeys. Many people have great concern when it comes to any testing done 
on cats and dogs because they have more direct contact and experience with those types of 
animals. This same type of animal bias is true in religion. An ancient Hindu verse says he who 
kills, eats, or permits the slaughter of a cow will "rot in hell for as many years as there are hairs 
on the body of the cow so slain!" (Karanth, 2009).  In Buddhism, all animals are seen as sentient 
beings and are capable of the same amount of suffering as humans. In Judaism, certain animals 
may be killed but only if prepared a certain way.  Christianity is not very clear when it comes to 
animal rights, however some say that because everything is God‟s will, then so is animal 
experimentation.   
 With respect to transgenic environmental issues, the possible environmental impact that 
could from the accidental release of transgenic animals and plants is a clearer issue. Augmenting 
an animal‟s DNA can leave it bigger, faster, stronger, healthier, and more fertile than its natural 
counterparts.  Thus, the risk of these animals escaping from research facilities and going into the 
wild could have devastating effects on natural species.  
 
The Benefit of Transgenesis 
Individuals who are in favor of transgenesis argue mainly for the benefits of animals to 
medical research and food sources, both of which have the potential to save and prolong both 
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human and animal life. The benefits of using animals in transgenic research have already been 
greatly significant, and will continue to be in the future.  
As already stated in Chapter-2, hundreds of medical discoveries have come from the use 
of transgenic animals. Scientists using transgenics are continuing to use animals in a very 
creative ways, and with today‟s medical knowledge most animals are put through minimal 
amounts of pain, if any at all.  For example, transpharming is a great example of animal 
transgenics because there is a high scientific yield (the cheap production of human medicines) 
and virtually no cost in terms of suffering to the animal.  It is also important to note that not all 
medical studies serve purely a human purpose, veterinary medicine and all of its animal vaccines 
and treatments would not be anything without the use of animals in experimentation.  
 
Disease Model Ethics 
 A transgenic disease model is an animal that has incorporated a transgene that will allow 
the animal to have some of the symptoms of a human disease. This is a great tool that allows us 
to study a human disease and test potential cures or vaccines directly through an animal, before 
proceeding to test the treatments in humans.  The use of animals in this respect means that time, 
money, and side effects on human test subjects can be kept to a minimum.  
 The Alzheimer‟s disease model (discussed in Chapter-2) serves as an excellent case for 
discussing transgenic ethics for this class of animals.  Some quick facts about Alzheimer‟s can 
show just how serious of a condition it is.  In the US, as many as 5.3 million people in the US are 
living with Alzheimer‟s, in fact every 70 seconds someone develops Alzheimer‟s (Alz.org, 
2009).   It is the 7
th
 leading cause of death, and the direct and indirect costs of Alzheimer‟s and 
other dementias amount to $148 billion a year.  The Alzheimer‟s mouse was developed at WPI 
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by Prof Adams in collaboration with the former Transgenic Sciences Inc. (Worcester) (Games et 
al., 1995).  The animal proved that the production of toxic β-amyloid protein is sufficient for 
initiating the disease in the brain, and provided a model for rapidly screening potential 
therapeutics.  Elan Pharmaceuticals used this model to create the first test vaccine for 
Alzheimer‟s disease (Schenk et al., 1999).  In phase-I clinical trials, the vaccine was safe in most 
individuals tested, but a small percentage of patients experienced inflammation, so Elan is 
currently testing a second generation vaccine.  The research conducted using the Alzheimer‟s 
mouse line is easily seen as having a solid moral foundation, considering so many people are 
drastically affected worldwide, while there is no evidence of physical pain brought on by this 
genetic alteration.  To the author of this chapter, it is very clear in this case that this was an 
ethically acceptable practice of transgenic animal research. 
 
Xenotransplantation Ethics 
 Xenotransplantation is the use of animals to grow tissues or organs that can be used for 
transplantation into humans. Many people in this country die every year waiting for an organ 
transplantation that they never receive. One problem with using organs from another human is 
that the recipient‟s body will reject the foreign organ unless the donated organ is histocompatible 
with the recipient.  Surprisingly, pig organs are very similar to humans, and have been used for 
transplantation research.  However, implanting organs from another animal does not come 
without its risks, including immunorejection or viruses.  The biggest concern of using pig organs 
is spreading pig viruses to humans, for example as we currently worry about the current H1N1 
swine flu outbreak. This means that implanting a human with a pig organ could allow cross 
species infection (already proven for influenza virus), to create a new human strain of a virus 
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previously present only in pigs.  However, this might be prevented by screening the donated 
organs for known viruses beforehand.  Another argument against xenotransplantation is whether 
the pigs should be raised solely for human purpose, as they would be sacrificed to obtain the 
organs.  However, since animals are also raised to be eaten and therefore save lives, it can hardly 
be argued that animals cannot be raised to have their organs implanted instead of ingested, 
especially if the animals are humanely sacrificed.  
 
Transpharming Ethics 
 Transpharming is the use of animals to produce a desired a chemical or protein for 
pharmaceuticals. This technology is used most efficiently when the desired chemical is produced 
by the animal in their milk, as the produced protein has minimal effects on the animal‟s 
physiology.  This method requires almost no further purification of the product, and does not 
physically harm the animal.  Animals such as cows, sheep, and goats have been successfully 
used as transpharmers.  The author of this chapter believes there are no real ethical arguments 
against this type of trangenics, as there are strong medical benefits to society, with no observable 
animal suffering.  
 
Transgenic Food Source Ethics 
 In today‟s poor economy the high price of food is something that could be lowered for 
some items by the use of transgenic animals. Superfish are farm raised fish that have had their 
DNA altered so that they will grow larger, faster, on the relatively the same amount of food. 
Superfish appear to undergo no pain and are far better adapted to aquaculture than normal fish. A 
similar situation is seen with for maize that has been transgenically altered to grow faster and 
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yield a larger crop than the normal strain. World hunger continues to increase with an increasing 
population.   
 The alteration of plant genes has been going on for several years, and has had both 
positive and negative results.  As a positive example, plants such as tomatoes have been designed 
to grow bigger and faster with less watering, and to be less likely to bruise during shipping.  
People are typically less concerned with the well being of plants than with animals, but are 
seriously concerned with their environmental impact.  Much has already been accomplished 
altering a plant‟s DNA to allow it to benefit us.   As a negative example, Monsanto created 
“Round-up Ready Tomatoes” who‟s DNA was recombined to make it resistant to a certain type 
of herbicide. This meant that the herbicide could be sprayed on a crop of tomatoes and kill other 
weeds but not the tomato plants, yielding a larger crop.  But the environmental concern is that 
these genetically stronger plants will spread and wipe out the unaltered species. It is hard to 
control pollen spread by the wind, and to keep these genetically modified plants from spreading. 
 
Ethics and the Law 
 Ultimately it is left up to the politicians as influenced by society and their ethical beliefs 
to legislate laws on animal experimentation. This topic will be discussed in detail in Chapter-4. 
One group will continue to lobby for more research funding, while activists lobby for illegal use 
of all animal experiments.  Transgenics is not just a US issue, but is truly a global issue, so key 
questions will revolve around what persons or groups of people have the power to enact the laws 
that will control transgenic animals?  Transgenic science is happening very rapidly and new 
discoveries are made every day.  But with great knowledge comes great responsibility, and as a 
society we must make sure that our morals keep up with this new technology. 
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Chapter-3 Conclusions 
  In this chapter, the positives and negatives of transgenic animal use have been examined, 
and it is clear that in most cases the good outweighs the bad.  Animals have been used to better 
mankind for centuries.  The author of this chapter feels that transgenesis should continue, but 
with strong oversight to minimize animal suffering.   The use of animals for research must be 
continued, but under careful regulation. Transgenic animals can be a great benefit to our planet 
and can save the lives of generations to come. The next chapter will go into depth on the laws 
and regulations involved with transgenic animals.  
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Chapter 4: Transgenic Legalities 
Katherine McCormack 
 
Introduction 
Research involving transgenic animals has been on the forefront of the biotech industry 
since 1973 when the first genetically modified organism was created (Cohen et al., 1973).  In the 
form of recombinant bacteria, the first genetically modified organism immediately brought many 
ethical concerns to the public eye, including the safety of transgenic organisms and the processes 
used to create them.  Much of this controversy comes from the consumer side, questioning the 
possibilities of new and unnatural diseases or allergens that may be introduced though the 
production and consumption of the animals. Alongside consumer concerns are also industrial 
concerns.  Advances in transgenic technologies may allow some industries and even nations to 
thrive more than others when the medical benefits come fully to fruition.  Industries can gain 
recognition and boost the value of their patentable materials by integrating transgenic 
technologies into their work. 
Coinciding with these industrial and consumer concerns, many governmental bodies have 
been involved in overseeing transgenic research.   Governments have limited the use and 
patenting of genetically modified animals.  Investigating the advantages and disadvantages of 
transgenic animals helps governmental entities decide whether to patent these animals or restrict 
their use.  Looking at the outcome of various cases involving genetically modified organisms 
around the world helps in understanding the legalities surrounding this new technological 
process.  This chapter will document and describe the effects of transgenic technology on the 
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legal system, specifically the process of patenting life forms, and will use a specific landmark 
case (Oncomouse) to view various strategies when trying to patent a transgenic animal. 
 
Should Animals Be Patented:  Advantages and Disadvantages 
Types of Patents 
 When justifying the patentability of transgenic animals, it is best to first understand what 
can legally be classified as patentable material.  In the United States, the Patent and Trademark 
Office defines three types of patents:  utility patents, design patents, and plant patents.  Utility 
patents are granted to “anyone who invents or discovers any new and useful process, machine, 
article of manufacture, or composition of matter, or any new and useful improvement thereof.  
Design patents may be granted to anyone who invents a new, original, and ornamental design for 
an article of manufacture.  Plant patents may be granted to anyone who invents or discovers and 
asexually reproduces any distinct and new variety of plant” (USPTO, 2005).  These three types 
of patents clearly outline what a patent is, and what can be patented. 
 
Patentable Material 
 Along with the types of patents granted by the United States Patent and Trademark 
Office, patent laws govern how to obtain a patent and what material is patentable.  The 
patentable criteria do not state anything against animal patenting, but do not directly permit it 
either, so the controversy lies in this area.  The courts have to decide whether a genetically 
modified animal can be classified as patentable material.  The United States Supreme Court has 
focused on special categories not represented in the “patentable subject matter requirements. 
These categories include: 1) laws of nature, 2) natural phenomena, and 3) abstract ideas” 
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(Cornell University Law School, 2009).  Determining whether transgenic animals lie within 
these special categories is an important decision that directly impacts many people, domestically 
and globally. 
 
Effects of Transgenic Patents on Consumers 
 When deciding whether transgenic animals should be patented, it is important to look at 
the effects of such decisions on all parties that could be affected.  To do so, I have come up with 
four different areas to be addressed: the effects on consumers, industries, animals, and the 
environment.  Analyzing the possible advantages and disadvantages in relation to each of these 
four categories will aid in an overall conclusion whether animals should be patented.  In a later 
section I will discuss specific patent cases where various decisions have already been made to 
patent and not patent specific transgenic animals. 
 Transgenic animal production will likely have a large effect on consumer products in the 
future.  Transgenic animals “can be classified as: (1) models for the study of nutrition or 
diseases, (2) sources of modified food products, and (3) bioreactors that produce ingredients for 
nutritional products” (Prieto et al., 1999).  As we discussed in Chapter-2, we also document two 
additional classes of transgenic animals, xenotransplanters for creating transplant organs, and 
scientific models for studying the effects of a newly discovered proteins on physiology.  The 
possibilities to the consumer are endless, from salmon that grow to larger sizes with less food 
intake, to cows that produce life saving drugs in their milk.  The benefit to consumers was 
discussed in detail in Chapter-2, but some good examples are provided briefly here.  A good 
example is a transgenic cow that “produce(s) more milk, or milk with less lactose or cholesterol” 
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(Margawati, 2009).  A disease model for Alzheimer‟s disease (Games et al., 1995) has already 
served as a model for testing vaccines (Schenk et al., 1999) that are in human clinical trials.   
Another disease model is Oncomouse that develops cancer, was the world‟s first patented 
animal, and has already taught us information about cancer formation and has served to help 
screen drugs.  The ability to create a mouse that has cancer has opened up many doors in the 
medical field for testing possible cures.  The use of transgenic animals may lead to 
breakthroughs that could potentially save the lives of many people suffering from various 
diseases.  For all these various purposes, patenting transgenic animals looks positive for the 
future. 
 
Effects of Transgenic Patents on Industry 
 Pharmaceutical, agricultural, and material industries are among those who can benefit 
from transgenic animals.  In the material industry, animals can be used to produce a variety of 
products.  One example would be a transgenic goat that secretes spider silk in its milk.  The 
President and CEO of Nexia Biotechnologies stated that:   
 “spider silk is practically the world's strongest material…It's much stronger than 
steel -- five times as strong. We're going to make fishing lines out of it…Yes.  
Biodegradable fishing lines. Or maybe tennis racket strings…You could make 
hundreds of things out of spider silk, if only you could produce enough of it. 
Biodegradable sutures for surgery . . . replacement ligaments or tendons . . . 
hemostatic dressings . . . fashion. We call our product BioSteel'' (Osborne, 2002).   
 
There are many applications for transgenic animals in industry. There are unlimited ways that 
these animals can help us in the future.  Janine M. Benyus wrote a book entitled “Biomimicry” in 
1997. Over ten years ago she “observed that while humans create synthetic materials by means 
of high temperatures and pressures (''heat, beat, and treat'' methods, as they are known), nature 
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does so under life-friendly conditions. That is to say, in water, at room temperature, and without 
harsh chemicals” (Osborne, 2002).  This observation is interesting, making us think about the 
many factories we have, and all of the pollution that is seeping into our world.  Transgenic 
animals can be altered to produce many valuable industrial materials as well as medical products. 
Without the use of factories and the “heat, beat, and treat” method that Janine speaks of, 
production efforts, specifically those using transgenic animals, can be more efficient and less 
costly.  
Looking at the medical industry, there are a vast number of applications for transgenic 
animals. One that is particularly interesting is the use of transgenic pigs as possible organ donors. 
When any of the major human organs fail, the treatment is to replace them. This is extremely 
difficult because of a lack of donors.  Although there are many concerns about rejection of such 
organs, using transgenic pigs as donors is becoming more feasible. These pigs could be made to 
carry human antibodies that will lessen the possibility of rejection. Xenotransplantation, the 
transfer of tissue or organs from one species to another, “has been carried out at various times 
using non-human primates as donors.  Although use of non-human primates has enjoyed some 
very limited success, the very large number of organs needed impels consideration of non-
primates, such as the pig as organ donors” (Houdebine, 1997).  Perfecting this method using pigs 
by engineering them to not produce a sugar viewed as foreign to our immune system, will be a 
great advance in the medical technology industry. There is no doubt that transgenic animals will 
have a key role in the industrial world in the future, where patenting regulations are necessary for 
these animals.  
 One might question the usefulness of transgenic animals in developing countries that may 
not have the technologies to create such animals. However, transgenic technologies can be 
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beneficial to developing countries.  The use of transgenic technologies to create vaccines and 
medicines allows industries to make more of the product at a cheaper cost, for use worldwide.  
Also, some vaccines may prove to be edible, which greatly facilitates their administration in 
countries lacking extensive healthcare systems.  John McClellan, Director of Marketing at 
ProdiGene in College Station, Texas, says that “edible vaccines offer the ability to produce large 
volumes of proteins at very economical costs” (Mann, 2001).  Because of this economical cost of 
production, developing countries can purchase vaccines and medicines at a cheaper cost.  
Moreover, once the animals producing the vaccines are created, they can easily be bred to 
expand production, including in third world countries. 
 
Effects of Transgenic Patents on the Environment 
Although creating transgenic animals can benefit consumers and companies, they might 
pose threats to the environment.  The environmental concerns associated with transgenic animals 
include the possibility that transgenic animals could escape from their containment, 
outcompeting or interbreeding with wild type populations.  Studies have been conducted by the 
United States National Research Council (NRC), along with other groups, to investigate the 
potential environmental impact of transgenic animals and technologies. “These studies conclude 
that GM animals may have either positive or negative effects on the environment, depending on 
the particular animal, trait and environment into which it is introduced” (Green Facts, 2009).  
Taking into account the many different transgenic animals that could be created, the 
impact on the environment could eventually be staggering, unless controls are rigidly enforced, 
such as engineering them to die off unless a special nutrient is provided.  Researchers are 
analyzing each case individually.  One case gathering special environmental interest is the 
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breeding of rapidly-growing salmon, as these fish are close to being ready for commercial 
aquaculture.  The environmental concerns related to this type of fish include possibilities of the 
salmon escaping and breeding with non-transgenic salmon, and various ways the salmon could 
respond to different levels of environmental stress.  “The ability of fish to respond to stress was 
not dramatically influenced by growth hormone (GH) transgenesis in the present study since 
neither physiological stress response nor the cellular stress response was affected by elevated 
temperature treatments. By contrast, GH transgenic mice carrying an MT promoter appeared to 
experience a heightened physiological stress response” (Jhingan et al., 2003).  Unlike the GH 
mice, the superfish did not respond to different levels of stress, so GH animals are not all alike in 
their stress responses.  This creates a level of uncertainty when considering what will happen if 
transgenic animals are introduced into a natural habitat and encounter various stresses. 
With respect to the salmon escaping to interbreed with wildtype salmon, although 
Aquabounty Inc. (the company nearest to marketing superfish) has enforced rigorous rules for 
preventing fish escape, accidents could still happen. “The potential spread of transgenes to native 
populations of fish is of high concern should transgenic fish escape into open waters” (Wong 
2008). The outcome cannot be predicted with certainty, but there is a large concern that the 
salmon will wipe out native salmon. Containment arrangements for transgenic animals, including 
fish, must be regulated and thoroughly tested.  Engineering to hinder survival in the wild would 
add an extra safety feature. 
 
Effects of Transgenic Patents on the Animals 
Transgenically modified animals, and indeed animal research in general, has become a 
fundamental tool in the field of biomedical research.  Similarities between humans and animals 
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have helped in finding cures for many diseases, but there are many characteristics and diseases 
that humans do not share with any other species. The use of transgenic technologies allows 
researchers to use animals to study and test cures for human diseases that animals may not have. 
While the benefits for humans look to be very positive, there are many negative ways in which 
these animals are affected by the gene transferred from another species.  As discussed in the 
previous chapter, many ethical concerns arise as people feel it is unfair to submit these animals 
to potential harm or a shortened life span.  
GlaxoSmithKline is a company that uses transgenic animals in their research.  According 
to their position on the Global Public Policy regarding transgenic animals:  
“Transgenic animals suffer more abnormalities than regular research animals. The 
introduction of DNA into an animal can be very complex, and the possible side 
effects can be difficult to predict.  Possible harms might arise from surgical 
techniques used to harvest and re-implant embryos; the collection of tissue from 
the tip of the tail for genotyping; and non-specific effects caused by damage to 
genes adjoining the altered area of DNA. Also reduced fertility and/or oversize 
fetuses may result from this technology. In most cases the mutations impact 
highly specific metabolic processes or cell receptors without actually causing 
disease, discomfort, pain or malformation in the animals. The legal controls for 
their use are very stringent and GSK devotes considerable resources to monitoring 
these animals” (GlaxoSmithKline, 2009).  
 
Thus, there is a high concern about the welfare of the animals affected by transgenic 
technologies.  Although transgenic technologies allow companies to use fewer normal animals in 
their research, the possible animal defects and death rates are alarming. Figure-1 shows the 
survival rates of transgenic mice (open circles and triangles) in comparison to non-transgenic 
mice (black circles and triangles). It is clear that for this particular example, transgenic animals 
do live a shorter life, suffering a low survival rate.  Factors such as this complicate the decision 
whether to patent transgenic animals.   
 
53 
 
 
Figure 1.  Survival Rate Comparison of Transgenic Versus Non-Transgenic Mice.   
http://www.ehponline.org/members/1998/Suppl-1/57-69yamamoto/yamamotofig2big.GIF 
 
  
Transgenic Regulations 
Considering all of the advantages and disadvantages for consumers, industries, the 
environment, and the transgenic animals themselves, decisions must be made whether to patent 
transgenic animals. Organizations around the world are coming up with guidelines to help the 
decision making process. In this section, I will discuss patent making decisions made by different 
countries. We will see that transgenic animal use and research are valued on different levels 
throughout the world.   
 
U.S. FDA Guidelines 
The United States FDA released its guidelines on January 15
th
, 2009.  These guidelines 
address the way that transgenic animals should be considered under United States Law.  
Currently, three organizations are responsible for biotechnology products in the Unites States: 
“The FDA is responsible for regulation of food, feed, human drugs, and animal 
drugs; the EPA regulates pesticides and toxic substances; and the USDA oversees 
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meat, poultry, and egg products, plant pests and noxious weeds, and animal 
biologics…Transgenic animals may be regulated by the FDA under the theory 
that the genetic manipulation is an animal drug, and if the genetic change 
produces either a drug, food, or biologic, then that product may also be regulated 
by the FDA. The potential for EPA regulation exists if the transgenic animal 
produces potentially toxic chemicals” (Biotechnology, 2009).   
 
The FDA has chosen to categorize a transgenic animal as a food, drug, or chemical.  They have 
determined that transgenic animals will mostly be classified as an animal drug, the drug being 
the piece of DNA inserted into the animal. The newly categorized transgenic animals must fall 
under the existing requirements for regularly bred animals, given hormones or antibiotics, before 
they can be authorized for public use.  
 However, some concern comes from the public about the decision of the FDA to 
categorize transgenic animals in this manner.   The FDA does not regulate the processes used to 
make the product, but regulates the nutritional value of the food.   This means that “if the food 
product is 'materially different' from a conventional product, then the FDA can require that it be 
labeled.  But the FDA does not currently require that a pork chop be labeled whether it came 
from a pig produced through artificial insemination or by conventional breeding” (Adams, 2009).  
Similarly, the FDA is not required to label food products from a transgenic animal if it is 
nutritionally the same as a conventionally bred animal.  These FDA guidelines are a great start to 
categorizing transgenic animals, but there remains a sense of public uneasiness about transgenic 
products in the future, especially if they are not labeled. 
 After the release of the FDA guidelines, there was a 60 day commenting period where 
anyone could share their thoughts about the guidelines.  Thousands of comments and questions 
were raised about the safety of the animal products and how these products get to the market.  
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Questions like these have come up around the world, not just in the United States.  Product 
acceptance studies were conducted in the Netherlands and it was found that: 
 “Acceptance problems with the introduction of a new technology, like 
biotechnology, cannot be solved by public information campaigns alone. True 
enough, public information is a clear necessity, but there are two complicating 
factors: first, higher levels of knowledge about biotechnology do not necessarily 
coincide with higher levels of acceptance and, second, it is not reasonable to 
expect that the public will adapt totally to the new developments” (Hamstra and 
Smink, 1996).   
 
It is clear that despite the efforts around the world to regulate transgenic technologies, further 
efforts must be made to make the public aware of the safety of the animals, and the benefits they 
can have for humans around the world.    
 
Canadian Council for Animal Care Guidelines 
Another effort to regulate the integrating of transgenic animals into the world is to clearly 
regulate how the animals are contained, and requiring procedures in case of a transgenic animal 
breach.  In Canada the Canadian Council for Animal Care (CCAC) has provided guidelines for 
transgenic animals, of which one section is specifically dedicated to their containment.  The 
guidelines read as follows: 
Containment for Transgenic Animals: 
i. All proposals for creation or use of transgenic animals must assure the ACC that 
risks to human health and the environment are minimized to an acceptable level. 
For transgenic animals created using micro-injection or replication-defective 
viruses, the containment risks are limited to those associated with the escape of 
the animal and interbreeding with wild stocks. Proposals should include 
information about: 
o containment and security procedures in animal facilities and, if applicable, 
during transportation when importing the animal; 
o plans for recapture should a breach of containment occur; and 
o The consequences to human health or wild populations should 
containment fail. 
56 
 
 
ii. For commonly-used transgenic species, each animal facility should have SOPs for 
containment, which can be referenced by proposals. 
 
iii. ACCs should discuss with the institutional Biohazard Committee any proposal 
which raises biohazard containment concerns.  (CCAC Guidelines, 2005) 
 
These Canadian guidelines when followed should show that procedures dealing with transgenic 
animals and technologies have been devised and aim to protect the public against any problems 
that may occur if a transgenic animal is integrated into the wild by accident.  The CCAC 
understands that transgenic technologies are new and rapidly developing.  For this reason, the 
guidelines presented above are subject to review at least every two years.  This constant review 
and updating is a great way to stay on top of regulating the rapidly developing issues surrounding 
transgenic animals.  
 
Transgenic Case Study:  Oncomouse 
 After investigating the advantages, disadvantages, and actions taken to regulate 
transgenic animal use, the specific case of Oncomouse can now be used to observe the decision 
making process about whether to patent a transgenic animal.  Oncomouse was produced at 
Harvard medical school in the 1980‟s (Leder and Stewart, 1984).  This transgenic mouse was 
created to have a high potential for getting cancer.  Since the mouse had great value in the 
growing search for a cure for cancer, Harvard sought to obtain a patent in the United States, and 
eventually in other countries.  Currently in the United States and Europe, universities are legally 
obliged to patent and publicize any intellectual property that comes from governmentally funded 
projects.  As discussed in the previous chapter, the Oncomouse case was one of the first to raise 
the issue of morality concerning transgenic animals. Is it right to patent “animals or animal 
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varieties, particularly for higher-order animals such as mammals, even if they do otherwise meet 
patentability criteria” (Bioethics and Patent Law, 2006).  In the United States, Europe, and 
Canada, Oncomouse patent decisions were made, all with different processes and outcomes.  
 Patent law covers inventions and discoveries, but there is a clear distinction between the 
two.  If one makes a scientific discovery of a naturally occurring phenomenon, the discovery is 
not patentable.  If something is invented that has been constructed using artificial materials and 
processes, the invention is patentable.  Because genes are naturally created, it is hard to decide if 
they are patentable.  A transgenic animal is created using artificial processes, but holds natural 
genes that were discovered, not created by any process.  One can argue that because the gene is 
not specifically something that is created or invented there should be no patent granted.  When 
trying to obtain a patent on a gene, a scientist must “isolate it from its natural state and identify 
an industrially useful property for it” (Exploiting Abstract, 2004).  In the case of Oncomouse, the 
gene is useful because it aids in finding a cure for cancer.   
 
U.S. Oncomouse Case 
In 1988, the United States Patent Office granted a patent to Harvard University.  The 
patent was granted for a “transgenic non-human mammal whose germ cells and somatic cells 
contain a recombinant activated oncogene sequence introduced into said mammal” (Bioethics 
and Patent Law, 2006).   The oncogene could be isolated and it was proven to be useful for the 
biomedical industry.  “Harvard initiated the commercial cycle of credit in 1988 when the 
oncomouse patent was granted and licensed to DuPont giving the firm an exclusive license to the 
sweeping coverage of the transgenic landscape embodied in the patent.  The license gave the 
firm the control it needed to start the transformation of property rights into financial revenues” 
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(Murray, 2007).  Since the patent was initially licensed to DuPont in 1988, transgenic 
technologies have subsequently evolved, and now hold a prominent role in the biomedical field 
as well as farming and material industries. 
 
Oncomouse Case in Europe 
While the United States Patent Office chose to grant a patent for Oncomouse, the 
European Union prolonged the decision making process.  In May of 1985, the president of 
Harvard College applied for a European patent, specifically for the method of creating transgenic 
animals.  In 1989, the European Patent Office rejected the patent for Oncomouse. There were 
two main reasons for this rejection.  First, the European Patent Convention (EPC) states in 
“Article 53b...animal varieties are not patentable” (Dutfield and Suthersanen, 2008).  Second, 
Article 83 of the EPC says that the application must be specific enough for somebody skilled in 
the field to be able to repeat and carry out the process.  The application was not specific enough.  
The wording in the application included „all non-human animals‟, not specifically mice.   
In 1990, under an appeal, the decision was made that transgenic animals were not an 
animal variety.  The Examining Division was asked to reconsider how they had interpreted the 
patent application. They also took under consideration Article 53a of the EPC, which considers 
public morality and ethics.  If the patent would be contrary to the public and their morality, then 
the patent would not be granted.  The Technical Board of Appeal (TBA) came up with a 
balancing test to help decide if the public was generally for or against the patenting of transgenic 
processes on animals. The study also investigated whether the technologies were harmful to the 
animals and the environment.  The conclusions were in favor of the patent application, and in 
October of 1992, a patent was granted by the EPO.  Since then there has been several situations 
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where the TBA has had to review the Oncomouse patent because of questions on its validity, but 
each time they decided the patent is still valid.  This ongoing process shows that transgenic 
technologies are still a growing issue, with many different jurisdictions. 
 
Canadian Oncomouse Case 
Contrary to the decisions in the United States and Europe, Canada chose not to patent the 
Oncomouse.  The case in Canada is very interesting because they faced the decision with a 
different strict approach.  The rejection of the patent claim was caused specifically by the 
language of the claim.  The words „manufacture‟ and „composition of matter‟ were interpreted 
differently by the Canadian court.  The Canadian Patent Office originally rejected the claims for 
the animal product, but approved the process used to create the animals.   
After the original rejection of the patent, the Federal Court, on an appeal, ruled that 
Oncomouse was in fact a composition of matter and granted a patent to Harvard College.  Since 
the process used to create the mouse could easily be duplicated the Federal Court decided that it 
was patentable material.  But by 2002, on another appeal, the case was brought to the Supreme 
Court for a ruling.  They decided that the two terms, manufacture and composition of matter, 
were too broad and did not eliminate the use of higher life forms. This led to the court drawing a 
distinct line between what life forms were counted as higher forms and what life forms could be 
patented.  The court decided that a mouse could not be considered a composition of matter.  
The Supreme Court did not grant a patent because they did not find sufficient reasons to 
deviate from the original patent law as they interpreted it.  From 2000 until 2003, many 
arguments were made for and against patenting Oncomouse. After a long process of patent 
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claims, approvals, and appeals, the final decision in Canada was Oncomouse and the processes 
used to create Oncomouse, are not patentable material 
Looking at these three different cases regarding the patenting of Oncomouse, it is clear 
that different governmental entities are going to have different opinions and interpret animal 
patenting in different ways.  Recommended regulations as discussed in the previous section will 
help serve as landmark cases to lessen subsequent legal controversy surrounding transgenic 
animal processes.  Transgenic technologies have a rising importance in the biomedical field as 
well as agriculture and other industries.  The case of Oncomouse has paved the way for many 
other transgenic animal patents to come. 
 
Chapter-4 Conclusions 
 When considering whether to patent life forms it is important to take into consideration 
all parties that will be affected by the decision.  Over the past few decades transgenic 
technologies have been of rising importance in the biomedical, pharmaceutical, farming, and 
material industries.  The use of transgenic animals as disease models and pharmaceutical 
producers shows a promising positive impact for mankind in the future.  It is important that these 
animals are patented to protect the industries and consumers alike.  Continuing growth of 
transgenic animal research and use around the world shows that these animals are going to hold a 
strong position in the lives of future generations.  However, regulations should be rigorously 
enforced to help ensure transgenic animals are not released into the wild, and if so, show 
diminished survivability relative to wild populations.  But regulations will not be enough to 
contain public uneasiness toward the new technologies.  Education about these animals can ease 
some of the controversy, but can never make it go away.  There will be many legal cases to come 
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from these animals and technologies, many courts will have to make decisions whether to patent 
a particular animal.  More regulations and laws are inevitably going to be made to aid in this 
decision making process. 
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PROJECT CONCLUSIONS 
 
In biological and medical research, transgenic animals have already proven to be 
invaluable, serving as models for testing new therapies for diseases, serving as bioreactors for 
producing human drugs, and providing information on the function of newly discovered proteins.  
In the near future, transgenic animals may also provide organs for transplant, and may provide 
aquafarmed salmon for human consumption.  In spite of these vast benefits to society, transgenic 
animals also have a variety of ethical issues, including the welfare of the animals themselves,  
which must be balanced against societal gains.  Based on the research performed in this project, 
the authors conclude the following about the field of transgenesis.  We believe that all of the 
above mentioned types of transgenesis should continue, as each type mentioned provides strong 
benefit to society.  In most cases, the animals do not suffer, but in those cases where animal 
suffering is observed (i.e. for Oncomouse) we believe in strong IACUC and FDA oversight to 
ensure suffering is minimized by using painkillers or euthenasia.  Although the growth hormone 
experiments with fish provide a transgenic success story, the same types of GH experiments with 
mammals (i.e. Superpig) failed by not providing strong benefits to society, and the animals 
suffered needlessly, so we agree with the current moritorium on such experiments.  We applaud 
the new FDA guidelines for patenting transgenic animals and their products.  They are long 
overdue, and should help standardize the industry, while providing strong oversight to help 
ensure animal health and helping prevent environmental disasters.   
 
